Opportunity Information: Apply for PA 16 231
Apply for PA 16 231
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Non-healing Ulcerative Wounds in Aging (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866,.
- This funding opportunity was created on May 06, 2016 and posted on May 06, 2016.
- Applicants must submit their applications by Sep 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Non-healing Ulcerative Wounds in Aging (R21) funding opportunity (PA 16-231) is a discretionary NIH grant announcement released by the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH). It supports exploratory and early-stage research projects using the R21 mechanism, with the overall aim of improving understanding and care of chronic, non-healing ulcerative wounds in the context of aging. The program is centered on the scientific and clinical challenges that make ulcerative wounds persist in older adults, as well as the downstream consequences these wounds have on health, function, and quality of life.
The FOA is open to a wide range of applicants, reflecting NIH's intent to bring together many sectors that can contribute to wound research and translation. Eligible applicants include federal-recognized tribal governments and other tribal organizations, state and local governments (including counties, cities, townships, special districts, and public housing authorities), public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses), and other entities as described in the full eligibility language. In practice, this broad eligibility supports proposals from universities, medical centers, health systems, community-based organizations, research institutes, and industry partners, including those working on diagnostics, therapeutics, devices, and care delivery innovations.
From a research standpoint, the announcement invites applications spanning basic, clinical, and translational approaches, as long as they are clearly tied to non-healing ulcerative wounds in aging or in older persons. Priority areas include (1) studies of the biology, etiology, and pathophysiology of non-healing ulcerative wounds, which may be investigated in animal models and/or directly in older adults; (2) projects that translate findings from basic or clinical research into clinical practice and health decision-making, meaning work that helps move evidence toward real-world use by clinicians, patients, caregivers, and health systems; and (3) research focused on diagnosis, prevention, management, and clinical outcomes of non-healing wounds in older adults, which can include evaluating how wounds are identified, how risk is reduced, how treatment strategies perform, and what outcomes matter most for older patients.
Financially, the opportunity lists an award ceiling of $200,000, aligning with the R21’s role in supporting smaller, innovative projects that generate preliminary data or test new concepts rather than large-scale definitive trials. The activity category is Health, and the CFDA (assistance listing) numbers associated with this opportunity are 93.866 (with the announcement also listing 93.866 again in the source data). The posting and creation dates are May 6, 2016, and the closing date shown is September 7, 2019 (both original and current closing date). While the source excerpt does not specify the exact number of expected awards, the listing indicates that awards were anticipated under the announcement.
Overall, this FOA is designed for investigators proposing well-justified, innovative R21 projects that can advance the science of chronic wound persistence in older populations and help close gaps between mechanistic knowledge, clinical interventions, and practical decision-making. Strong applications under this announcement would typically make a clear connection to aging-related factors that influence wound healing, articulate a plausible pathway from the proposed work to improved prevention or management, and define meaningful clinical or translational outcomes relevant to older adults.
FAQs: Non-healing Ulcerative Wounds in Aging (R21) - PA 16-231
What is the Non-healing Ulcerative Wounds in Aging (R21) funding opportunity?
This is a discretionary NIH grant opportunity (PA 16-231) released by the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH). It supports exploratory and early-stage research projects using the R21 mechanism, focused on improving understanding and care of chronic, non-healing ulcerative wounds in the context of aging.
What is the main purpose of this FOA?
The purpose is to advance science and care related to chronic, non-healing ulcerative wounds in older adults. The announcement emphasizes the scientific and clinical challenges that cause ulcerative wounds to persist in older persons, along with the downstream consequences for health, function, and quality of life.
What type of grant mechanism does this opportunity use?
The opportunity uses the NIH R21 mechanism, which is intended for exploratory and early-stage research. Projects are generally positioned to test new concepts or generate preliminary data rather than to run large, definitive trials.
What research topics does the program prioritize?
The FOA invites basic, clinical, and translational research as long as it is clearly tied to non-healing ulcerative wounds in aging or in older persons. Priority areas include:
- Biology, etiology, and pathophysiology of non-healing ulcerative wounds (in animal models and/or directly in older adults)
- Translation of findings into clinical practice and health decision-making (moving evidence toward real-world use by clinicians, patients, caregivers, and health systems)
- Diagnosis, prevention, management, and clinical outcomes in older adults (including identification, risk reduction, treatment performance, and outcomes that matter to older patients)
Is this FOA limited to clinical research, or can it include basic and translational work?
It can include basic, clinical, and translational approaches. The key requirement described is that the project must be clearly connected to non-healing ulcerative wounds in aging or older persons, and aligned with the FOA's stated priority areas.
Does the FOA allow studies using animal models?
Yes. The FOA explicitly notes that studies of the biology, etiology, and pathophysiology of non-healing ulcerative wounds may be investigated in animal models and/or directly in older adults.
Does the FOA encourage projects that support real-world clinical decision-making?
Yes. One of the priority areas is translating findings from basic or clinical research into clinical practice and health decision-making, including work that helps clinicians, patients, caregivers, and health systems use evidence in real-world settings.
What kinds of outcomes are considered relevant under this opportunity?
The FOA highlights downstream consequences and outcomes tied to older adults, including impacts on health, function, and quality of life. It also references clinical outcomes relevant to diagnosis, prevention, management, and treatment performance in older patients.
Who is eligible to apply?
The FOA is open to a wide range of applicants. Eligible applicants include federal-recognized tribal governments and other tribal organizations; state and local governments (including counties, cities, townships, special districts, and public housing authorities); public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including small businesses); and other entities as described in the full eligibility language.
Are for-profit organizations and small businesses allowed to apply?
Yes. The eligibility language includes for-profit organizations, including small businesses.
Are tribal governments and tribal organizations eligible?
Yes. The FOA lists federal-recognized tribal governments and other tribal organizations among eligible applicants.
Are state and local government entities eligible?
Yes. The FOA includes state and local governments, specifically mentioning counties, cities, townships, special districts, and public housing authorities.
Are universities and medical centers appropriate applicants under this FOA?
Yes. Public and private institutions of higher education are eligible, and the broad eligibility is described as supporting proposals from universities, medical centers, health systems, research institutes, community-based organizations, and industry partners.
Can nonprofits without 501(c)(3) status apply?
Yes. The eligibility description includes nonprofit organizations with or without 501(c)(3) status.
What is the maximum award amount listed for this opportunity?
The opportunity lists an award ceiling of $200,000, consistent with the R21 mechanism's role in supporting smaller, innovative projects.
How does the award ceiling relate to the type of work expected?
Based on the description provided, the $200,000 ceiling aligns with the R21 intent to support innovative, early-stage projects that generate preliminary data or test new ideas, rather than large-scale, definitive studies.
What is the activity category for this funding opportunity?
The activity category listed is Health.
What is the CFDA (Assistance Listing) number for this opportunity?
The CFDA (assistance listing) number associated with this opportunity is 93.866 (it is listed as 93.866 in the source data).
When was this FOA posted, and what dates are shown for the opportunity?
The posting and creation dates are May 6, 2016. The closing date shown is September 7, 2019 (listed as both the original and current closing date in the source excerpt).
Does the opportunity specify the number of awards expected?
The source excerpt does not provide an exact number of expected awards. It indicates that awards were anticipated under the announcement.
What kinds of organizations does NIH appear to be trying to engage through this FOA?
The eligibility is intentionally broad and is described as supporting many sectors involved in wound research and translation. Examples mentioned include universities, medical centers, health systems, community-based organizations, research institutes, and industry partners, including those working on diagnostics, therapeutics, devices, and care delivery innovations.
What makes a project a good fit for this FOA based on the description?
Based on the provided summary, strong projects would typically: (1) clearly connect the proposed work to aging-related factors that influence wound healing, (2) address key scientific or clinical barriers to healing in older adults, (3) describe a plausible pathway toward improved prevention or management, and (4) define meaningful clinical or translational outcomes relevant to older persons.
Browse more opportunities from the same category: Health
Next opportunity: Youth Engagement, Edcuation, and Employment Programs
Previous opportunity: BLM AZ CESU CCS Wildlife Water Catchment Reconstruction/Repair Arizona Strip District AZ
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 231
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 231) also looked into and applied for these:
| Funding Opportunity |
|---|
| Comprehensive Alcohol Research Centers (P60) Apply for RFA AA 17 002 Funding Number: RFA AA 17 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,250,000 |
| Novel Approaches to Understanding, Preventing and Treating Lyme Disease and Tick-borne Coinfections (R21) Apply for PA 16 244 Funding Number: PA 16 244 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Mechanisms Mediating Osteoarthritis in Aging (R21) Apply for PA 16 240 Funding Number: PA 16 240 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Behavioral Health Workforce Education and Training (BHWET) for Paraprofessionals and Professionals Apply for HRSA 16 193 Funding Number: HRSA 16 193 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology (P30) Apply for PAR 16 247 Funding Number: PAR 16 247 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE)(P20) Apply for PAR 16 241 Funding Number: PAR 16 241 Agency: HHS-NIH11 Category: Health Funding Amount: $1,500,000 |
| Mechanisms Mediating Osteoarthritis in Aging (R01) Apply for PA 16 239 Funding Number: PA 16 239 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Impact of Aging in Human Cell Models of Alzheimer's Disease (R01) Apply for RFA AG 17 009 Funding Number: RFA AG 17 009 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Specialized Alcohol Research Centers (P50) Apply for RFA AA 17 001 Funding Number: RFA AA 17 001 Agency: HHS-NIH11 Category: Health Funding Amount: $1,150,000 |
| Novel Approaches to Understanding, Preventing and Treating Lyme Disease and Tick-borne Coinfections (R01) Apply for PA 16 243 Funding Number: PA 16 243 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Nathan Shock Centers Coordinating Center (U24) Apply for RFA AG 17 008 Funding Number: RFA AG 17 008 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
| Informatics Methodology and Secondary Analyses to Explore Shared Immunology Study Data in ImmPort (UH2) Apply for PAR 16 253 Funding Number: PAR 16 253 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Ryan White HIV/AIDS Program Building Care and Prevention Capacity: Addressing the HIV Care Continuum in Southern Metropolitan Areas Apply for HRSA 16 187 Funding Number: HRSA 16 187 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| From Association to Function in the Alzheimers Disease Post Genomics Era (R21) Apply for RFA AG 17 011 Funding Number: RFA AG 17 011 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Centers of Research Translation (CORT) (P50) Apply for RFA AR 17 001 Funding Number: RFA AR 17 001 Agency: HHS-NIH11 Category: Health Funding Amount: $1,000,000 |
| Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Tuberculosis Vaccine Design (R01) Apply for PAR 16 254 Funding Number: PAR 16 254 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Mississippi Delta Health Collaborative Apply for CDC RFA DP16 1612 Funding Number: CDC RFA DP16 1612 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $3,150,000 |
| Public Health Preparedness and Response (PHPR) Cooperative Agreement for All-Hazards Public Health Emergencies: Zika 2016 Apply for CDC RFA TP16 1602 Funding Number: CDC RFA TP16 1602 Agency: HHS-CDC-OPHPR Category: Health Funding Amount: $5,000,000 |
| Grants for Early Medical/Surgical Subspecialists' Transition to Aging Research (GEMSSTAR) (R03) Apply for RFA AG 17 012 Funding Number: RFA AG 17 012 Agency: HHS-NIH11 Category: Health Funding Amount: $75,000 |
| From Association to Function in the Alzheimers Disease Post Genomics Era (R01) Apply for RFA AG 17 010 Funding Number: RFA AG 17 010 Agency: HHS-NIH11 Category: Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 231", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.